NCT06652555View on ClinicalTrials.gov

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

September 29, 2026

Study Completion Date

September 29, 2027

Conditions
ALKNSCLC
Interventions
OTHER

Group 1

without Intervention

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06652555 - The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study | Biotech Hunter | Biotech Hunter